Gamma-aminobutyric acid type A receptor alpha-1 beta gamma-2 (α1βγ2 GABAA receptor) (α1βγ2 GABAA receptor)

The Gamma-aminobutyric acid type A receptor alpha-1 beta gamma-2 (α1βγ2 GABAA receptor) is the most abundant GABAA receptor subtype in the mammalian central nervous system, accounting for a significant portion of inhibitory signaling in the cerebral cortex and cerebellum (Source: StatPearls, GABA Receptor). It is a heteropentameric ligand-gated ion channel that facilitates the influx of chloride ions upon binding of the neurotransmitter GABA, leading to neuronal hyperpolarization and a subsequent decrease in neuronal excitability (Source: UniProt, P14867). This specific receptor configuration is characterized by its high sensitivity to benzodiazepines and 'Z-drugs' like zolpidem, which bind to a distinct allosteric site at the interface of the α1 and γ2 subunits (Source: IUPHAR/BPS Guide to Pharmacology). Clinically, the α1-containing subtype is primarily responsible for the sedative, anticonvulsant, and amnestic properties of GABAergic drugs, making it a primary target for treating insomnia and acute seizures (Source: PubMed, PMID 22300236). However, chronic modulation of this receptor is associated with the development of pharmacological tolerance and physical dependence (Source: NIH, MedlinePlus). Mutations in the genes encoding these subunits, such as GABRA1 or GABRG2, are frequently implicated in genetic epilepsy syndromes (Source: PubChem).

Other names

BZ1 receptorBenzodiazepine receptor 1Omega-1 receptorGABRA1-containing GABAA receptorAlpha-1-selective GABAA receptorGABRA1/GABRB/GABRG2 complex

Positive allosteric modulation (PAM) at the alpha-gamma subunit interface, which increases the frequency of chloride channel opening in response to GABA binding, thereby enhancing inhibitory postsynaptic potentials and reducing neuronal firing (Source: StatPearls, Benzodiazepines).